Radiopharm Theranostics (ASX:RAD) partnered with Nasdaq-listed Lantheus to develop oncology radiopharmaceuticals in Australia, according to a Monday filing with the Australian bourse.
The partnership will see the company lead clinical development efforts, with Lantheus covering costs associated with the program, the filing said.
The company will receive up to $2 million in milestone payments for achieving key clinical development objectives, such as ethics committee approval, first patient dosing, and patient enrollment for the first imaging trial, according to the filing.
Radiopharm Theranostics shares rose nearly 9% in morning trade Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.